Axillary recurrences following positive sentinel lymph node biopsy with individual tumor cells or micrometastases and no axillary dissection

Breast Disease

Volumn 31, Issue 2, 2010, Pages 83-90

  Erb, Kathleen M ^a   ShapiroWright, Hilary M ^b   Julian, Thomas B ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b SSM St Clare Health Care   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOKERATIN;

ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL OBSERVATION; CYTODIAGNOSIS; DIAGNOSTIC ACCURACY; HUMAN; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MICROMETASTASIS; OVERALL SURVIVAL; PATIENT ATTITUDE; PATIENT SAFETY; PATIENT SELECTION; PRIORITY JOURNAL; RECURRENCE RISK; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RISK BENEFIT ANALYSIS; RISK FACTOR; SENTINEL LYMPH NODE BIOPSY; SURGICAL RISK; TUMOR CELL; TUMOR VOLUME;

AXILLA; BREAST NEOPLASMS; DECISION SUPPORT TECHNIQUES; FEMALE; HUMANS; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASTIC CELLS, CIRCULATING; RISK FACTORS; SENTINEL LYMPH NODE BIOPSY;

EID: 79952678764     PISSN: 08886008     EISSN: 15581551     Source Type: Journal    
DOI: 10.3233/BD-2010-0299     Document Type: Article

References (43)

1. U. Veronesi, V. Galimberti, G. Paganelli et al., Axillary metas-tases in breast cancer patients with negative sentinel nodes: a follow-up of3548 cases, EJC 45 (2009), 1381-1388.
2. D.N. Krag, S.J. Anderson, T.B. Julian et al., Technical out-comes of sentinel-lymph node resection and conventional axillary-lymph node dissection in patients with clinically node-negative breast cancer: results from the NSABP B-32 randomised phase III trial, Lancet 8 (2007), 881-888. (Pubitemid 47488052)
3. American Society of Clinical Oncology (ASCO) Website www.asco.org
4. NCCN Clinical Practice Guidelines in Oncology Breast Can-cer V.2.2.2010 www.nccn.org.
5. AJCC Cancer Staging Manual 7th Edition, New York; Springer (2010) pp. 364-365.
6. C. Cox, B. Centeno, D. Dickson et al., Accuracy ofintraoper-ative imprint cytology for sentinel lymph node evaluation in the treatment ofbreast carcinoma a 6-year study, Cancer 105 (2005), 13-20. (Pubitemid 40321478)
7. K. Motomura, S. Nagumo, K. Yoshifumi et al., Intraoperative imprint cytology forthe diagnosis ofsentinel node metastases in breast cancer, Breast Cancer 14 (2007), 350-353.
8. S. Krishnamurthy, F. Meric-Bernstam, A. Lucci et al., A prospective study comparing touch imprint cytology, frozen section analysis, and rapid cytokeratin immunostain for inter-operative evaluation of axillary sentinel lymphnodes inbreast cancer, Cancer 115 (2009), 1555-1562.
9. K.J. Van Zee, D.M.E. Manasseh, J.L.B. Bevilacqua et al., A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy, Ann Surg Oncol 10 (2003), 1140-1151. (Pubitemid 40486808)
10. T.B. Julian, P. Blumencranz, K. Deck et al., Novel intraoper-ative molecular test for sentinel lymph node metastases in pa-tients with early-stage breast cancer, J Clin Oncol 26 (2008), 3338-3345.
11. S.L. Chen, F.M. Hoehne and A.E. Giuliano, The prognos-tic significant of micrometastases in breast cancer: a SEER population-based analysis, Ann Surg Oncol 14 (2007), 3378-3384. (Pubitemid 350160103)
12. K. Y. Bilimoria, D.J. Bentrem, N.M. Hansen et al., Comparison of sentinel lymph node biopsy alone and completion axillary lymph node dissection for node-positive breast cancer, J Clin Oncol 27 (2009), 2946-2953.
13. R.F. Hwang, A.M. Gonzalez-Angulo, M. Yi et al., Low lo-coregional failure rates in selected breast cancer patients with tumor-positive centinela lymph nodes who do not undergo completion axillary dissection, Cancer 110 (2007), 723-730. (Pubitemid 47257646)
14. C.E. Cox, J.V. Kiluk, A.I. Riker et al., Significance ofsentinel lymph node micrometastases in human breast cancer, J Am Coll Surg 206 (2008), 261-268.
15. M.S. Pugliese, A.K. Karam, M. Hsu et al., Predictors ofcom-pletion axillary lymph node dissection in patients with im-munohistochemical metastases to the sentinel lymph node in breast cancer, Ann Surg Oncol 17 (2010), 1063-1068.
16. J. Reed, M. Rosman, K.M. Verbanac et al., Prognostic impli-cations ofisolated tumor cells and micrometastases in sentinel nodes ofpatients with invasive breast cancer: 10-year analysis of patients enrolled in the prospective East Carolina Univer-sity/Anne Arundel Medical Center sentinel node multicenter study, J Am Coll Surg 208 (2009), 333-340.
17. Y.G. Fan, Y.Y. Tan, C.T. Wu et al., The effect ofsentinel node tumor burden on non-sentinel node status and recurrence rates in breast cancer, Ann Surg Onc 12 (2005), 705-711.
18. K. Fournier, A. Schiller, R.R. Perry et al., Micrometastasis in the sentinel lymph node of breast cancer does not mandate completion axillary dissection, Ann Surg 239 (2004), 859-865. (Pubitemid 38669436)
19. K.E. Calhoun, N.M. Hansen, R.R. Turner and A.E. Giuliano, Nonsentinel node metastases in breast cancer patients with isolated tumor cells in the sentinel node: implications for completion axillary node dissection, Am J Surg 190 (2005), 588-591. (Pubitemid 41306082)
20. G. Cserni, S. Bianchi, V. Vezzosi et al., Validation ofclinical prediction rules for a low probability of nonsentinel and ex-tensive lymph node involvement in breast cancer patients, Am JSurg 194 (2007), 288-293. (Pubitemid 47225057)
21. C.H.M. van Deurzen, R. van Hillegersberg, M.G.G. Hobbe-link et al., Predictive value of tumor load in breast cancer sen-tinel lymph nodes for second echelon lymph node metastases, Cellular Oncology 29 (2007), 497-505. (Pubitemid 350136504)
22. G. Houvenaeghel, C. Nos, H. Mignotte et al., Micrometastases in sentinel lymph node in a multicentric study: predictive factors ofnonsentinel lymph node involvement-Groupe Des Chirurgiens De La Federation Des Centres De Lutte Contre Le Cancer, J Clin Oncol 24 (2006), 1814-1822. (Pubitemid 46638978)
23. G. Cserni, D. Gregori, F. Merletti et al., Meta-analysis of non-sentinel node metastases associated with micrometastatic sentinel nodes in breast cancer, Br J Surg 91 (2004), 1245-1252. (Pubitemid 39331448)
24. B. Fisher, C. Redmond, E.R. Fisher et al., Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation, N Engl J Med 312 (1985), 674-681. (Pubitemid 15134703)
25. J.S. Fant, M.D. Grant, S.M. Knox et al., Preliminary outcomes analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection, Ann Surg Oncol 10 (2003), 126-130. (Pubitemid 40485931)
26. J.M. Guenther, N.M. Hansen, L.A. DiFronzo et al., Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes, Arch Surg 138 (2003), 52-56. (Pubitemid 36055648)
27. A. Chagpar, L.P. Middleton, A.A. Sahin et al., Clinical out-come of patients with lymph node-negative breast carcinoma who have sentinel lymph node micrometastases detected by immunohistochemistry, Cancer 103 (2005), 1581-1586. (Pubitemid 40490018)
28. A. Haid, M. Knauer, R. Koberle-Wuhrer et al., Medium-term follow-up data after sentinel node biopsy alone for breast can-cer,Eur J Surg Oncol 32 (2006), 1180-1185. (Pubitemid 44793674)
29. S. Zakaria, G. Pantvaidya, C.A. Reynolds et al., Sentinel node positive breast cancer patients who do not undergo axillary dissection: Are they different? Surgery 143 (2008), 641-647.
30. C.S.E. Bulte, M. van der Heiden-van der Loo and A. Hennip-man, Axillary recurrence rate after tumour negative and mi-crometastatic positive sentinel node procedures in breast can-cer patients, a population based multicenter study, Eur J Surg Oncol 35 (2009), 25-31.
31. I. Langer, U. Guller, C.T. Viehl et al., Axillary lymph node dissection for sentinel lymph node micrometastses may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study, Ann Surg Oncol 16 (2009), 3366-3374.
32. S. Pernas, M. Gil, A. Benitezetal., Avoidingaxillarytreatment in sentinel lymph node micrometastases of breast cancer: a prospective analysis ofaxillary or distant recurrence, Ann Surg Oncol 17 (2010), 772-777.
33. D.N. Krag, S.J. Anderson, T.B. Julian et al., Primary outcome results of NSABP B-32, a randomized phase III clinical tri-al to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node-negative breast cancer patients, J Clin Oncol 28(18s) (suppl) (2010), abstr LBA505.
34. A.E. Giuliano, L. McCall, P. Beitsch et al., Local and regional control in breast cancer after sentinel node biopsy without axillary lymph node dissection: results from a randomized trial, Am Surgical Assoc 130th Annual Meeting Abstract (1 April 2010), 8-10
35. A.E. Giuliano, L.M. McCall, P.D. Beitsch et al., ACOSOG Z0011: A randomized trial ofaxillary node dissection in wom-en with clinical T1-2 N0 M0 breast cancer who have apositive sentinel node, J Clin Oncol 28(18S) (suppl; abstr CRA506), 2010.
36. V.C. Tjan-Heijnen, M.J. Pepels, M. de Boer et al., Impact of omission of completion axillary lymph node dissection (cAL-ND) or axillary radiotherapy (ax RT) in breast cancer pa-tients with micrometastases (pN1mi) or isolated tumor cells (pN0[i+]) in the sentinel lymph node (SN), Results from the MIRROR study, Abstract Presentation at ASCO Annual Meeting, (June 2009).
37. R.F. Hwang, S. Krishnamurthy, K.K. Hunt et al., Clinicopatho-logic factors predicting involvement of nonsentinel axillary nodes in women with breast cancer, Ann Surg Onc 10 (2003), 248-254. (Pubitemid 40486957)
38. C. Coutant, C. Olivier, E. Lambaudie et al., Comparison of models to predict nonsentinel lymph node status in breast can-cer patients with metastatic sentinel lymph nodes: a prospec-tive multicenter study, J Clin Oncol 27 (2009), 2800-2808.
39. T.B. Julian, S.J. Anderson, N. Golesorkhi et al., Predictive fac-tors for positive non-sentinel nodes following a positive sen-tinel node biopsy: NS ABP B-32, San Antonio Breast Cancer Symposium, Abstract 301 December, (2009).
40. A. Lucci, L.M. McCall, P.D. Beitsch et al., Surgical complica-tions associated with sentinel lymph node dissection (SLND) plus axillary lymph node dissection compared with SLND alone in the American College of Surgeons Oncology Group Trial Z0011, J Clin Oncol 25 (2007), 3657-3663. (Pubitemid 47372604)
41. I. Langer, U. Guller, G. Berclaz et al., Morbidity ofsentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery. A prospective Swiss multicenter study of 659 patients, Ann Surg 245 (2007), 452-461. (Pubitemid 46673142)
42. R.E. Mansel, L. Fallowfield, M. Kissin et al., Randomized multicenter trial of sentinel node biopsy versus standard ax-illary treatment in operable breast cancer: The ALMANAC Trial, JNatl Cancer Inst 98 (2006), 599-609. (Pubitemid 43904843)
43. T. Ashikaga, D.N. Krag, S.R. Land et al., Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection, J Surg Oncol (2010), 111-118.